All In Biotech

NDA 017892 · Pfizer

Halcion

Triazolam · Oral · Benzodiazepine

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Nov 15, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

17

2 Phase 3, 1 recruiting

FAERS reports

4,040

3,259 serious, 662 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . • The use of benzodiazepines, including triazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...

What it is approved for

From the label in effect Jul 10, 2026.

Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.

Mechanism: Triazolam is a benzodiazepine. Triazolam exerts its effect for the short-term treatment of insomnia through binding to the benzodiazepine site of the gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • HALCION · TRIAZOLAM 0.125MG · TABLET, ORAL · Prescription · TE AB
  • HALCION · TRIAZOLAM 0.25MG · TABLET, ORAL · Prescription · TE AB
  • HALCION · TRIAZOLAM 0.5MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Triazolam" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug abuse336
  • drug ineffective288
  • toxicity to various agents220
  • sopor208
  • overdose182
  • completed suicide172
  • fatigue165
  • nausea163
  • malaise155
  • drug interaction152
  • fall144
  • dizziness135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200494
200576
200676
200759
200867
200976
2010119
2011129
2012164
2013185
2014225
2015250
2016317
2017288
2018301
2019276
2020229
2021221
2022177
2023262
2024160
2025143
2026146

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Halcion (Triazolam)

2024 spending

$41K

Beneficiaries

83

202 claims

Per beneficiary

$493

$5.59 per unit

View as table
YearSpending
2020$108,803
2021$96,192
2022$37,314
2023$41,808
2024$40,938

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 439 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.